Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Mechanisms of Enzalutamide Resistance in mCRPC
NCT02099864Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Feb 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by OHSU Knight Cancer Institute. Started Feb 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02099864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099864.